News Source: Androscoggin News
| 2 months ago
Adolor Corp. acquired the worldwide rights Monday to OpRA III, a clinical-stage experimental drug with multiple potential uses, from Eli Lilly and Co...LLY) of Indianapolis $2 million upfront, royalties on net sales of any approved product, and up to...
News Source: Uinta County News
| 2 months ago
All Briefing.com news Micromet reports interim data from phase 1 study of BiTE antibody MT110 for the treatment of solid tumors Co presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell...
News Source: Uinta County News
| 2 months ago
All Briefing.com news Celsion announces that Data Safety Monitoring Board recommends continuation of it's Phase III ThermoDox study for primary liver cancer Co announces the Data Safety Monitoring Board has reviewed the safety data from the first...
News Source: The Noblesville Ledger
| 2 months ago
Eli Lilly and Co.'s OpRA III, an experimental medicine to restore bowel function in people taking narcotic painkillers. Exton, Pa.-based Adolor, the maker of constipation drug Entereg, will pay $2 million upfront to Indianapolis-based drug maker...
News Source: Androscoggin News
| 2 months ago
Cancer patients who receive chemotherapy are more likely to develop blood clots than other people, but now a new study says a blood-thinning drug could cut the risk in half. Besides posing a significant risk of problems in the heart, brain and lungs,...
News Source: Xtra News
| 2 months ago
Cancer patients whose tumors are targeted with heat treatment as well as chemotherapy are more likely to stay alive and cancer-free for longer than those who receive only chemotherapy, researchers said on Tuesday. The finding suggests it may be...